AtriCure (ATRC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Shares of AtriCure have returned +4.4% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. United States Revenue- Pain management: $17.27 million compared to the$16.17 million average estimate based on three analysts. The reported number represents a change of +35.6% year over year. International Revenue- Pain management: $1.79 million versus$1.92 million es ...